Fitzgerald Quoted on Insurance Providers’ Uncertainty about American Health Care Act
22 March 2017
Partner Kevin Fitzgerald was quoted in a New York Times article, “As Rivals Stand Silent, One Health Insurer Protests G.O.P. Plan,” covering insurance providers’ foresight for their plans under the American Health Care Act.
Fitzgerald explained that insurance providers “don’t have any real clear idea even see what a real clear path forward is going to look like … their business is months in the planning and sometimes years in the execution. They don’t even know if there will be an exchange in 2018.”
Fitzgerald explained that insurance providers “don’t have any real clear idea even see what a real clear path forward is going to look like … their business is months in the planning and sometimes years in the execution. They don’t even know if there will be an exchange in 2018.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”